Advancing Cancer Treatment Through Research & Innovation

Background The integration of dual HER2 blockade (trastuzumab + pertuzumab, PH) has improved outcomes in HER2-positive breast cancer, particularly in neoadjuvant and metastatic settings. However, evidence from routine clinical practice in low- and middle-income countries is limited. This study aimed to evaluate real-world survival outcomes, response rates, and safety of dual versus single blockade (trastuzumab alone, H) across treatment settings.

Background: Oligometastatic disease represents a biologically intermediate state where aggressive metastasis-directed therapy may improve durable disease control. Fractionated stereotactic radiotherapy (FSRT)enables safe delivery of ablative doses to intracranial and extracranial lesions. We report updatedoutcomes of linac-based FSRT with the inclusion of an additional patient.

MET amplification occurs in approximately 1-5% of treatment-naïve non- small cell lung cancer (NSCLC) cases. It can also develop as an acquired resistance mechanism, particularly after treatment with EGFR tyrosine kinase inhibitors (TKIs), where it's observed in about 15% of cases. This case underscores the coexistence of MET gene amplification and high PD-L1 expression in NSCLC, which has significant therapeutic implications. The presence of MET amplification suggests potential benefit from MET- targeted therapies, while high PD-L1 expression indicates responsiveness to immune checkpoint inhibitors. When MET amplification and high PD-L1 co-exist, the optimal treatment strategy can be challenging. The integration of molecular and immunohistochemical data guides personalized treatment strategies for this patient.

Triple negative breast cancer is the kind of breast cancer that does not have any receptors which are usually found in breast cancer. It is estrogen- receptor, progesterone-receptor, and HER-2 receptor negative. About 10-15% of all breast cancers are triple negative. Its commonly seen in women aged than 40 years, and those have a BRCA-1 mutation. This is a more aggressive form of cancer, harder to treat and has chances of recurrences. The single most prognostic factor is still the pathological complete response in case of neoadjuvant (NACT)settings.